What's Marc Dunoyer's mailing address?
Marc's mailing address filed with the SEC is C/O ORCHARD THERAPEUTICS PLC, 245 HAMMERSMITH ROAD, LONDON, X0, W6 8PW.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Orchard Therapeutics plc
Over the last 5 years, insiders at Orchard Therapeutics plc have traded over $14,660,920 worth of Orchard Therapeutics plc stock and bought 794,017 units worth $3,579,149 . The most active insiders traders include Capital Management, L.P.Ra ..., Llc Fmr, and Charles A Jr Rowland. On average, Orchard Therapeutics plc executives and independent directors trade stock every 116 days with the average trade being worth of $4,897,976. The most recent stock trade was executed by Frank E Thomas on 10 March 2023, trading 20,000 units of ORTX stock currently worth $9,200.
What does Orchard Therapeutics plc do?
orchard therapeutics is dedicated to bringing transformative gene therapies to children with life-threatening orphan diseases. we work in partnership with the world’s most prestigious research centres to harness the life-giving potential of gene therapy. orchard’s leadership team and collaborators have more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for orphan diseases. our mission is to provide the ideal environment and expertise to translate promising pre-clinical and early clinical results into commercially approved medicines available to patients around the world.
What does Orchard Therapeutics plc's logo look like?
Orchard Therapeutics plc executives and stock owners
Orchard Therapeutics plc executives and other stock owners filed with the SEC include:
-
Dr. Bobby Gaspar Ph.D., M.D.,
CEO, Member of Scientific Advisory Board & Exec. Director -
Frank E. Thomas,
Pres & COO -
Braden Parker,
Chief Commercial Officer -
Robin Kenselaar,
Sr. VP & GM of EMEA Commercial Operations -
Dr. Anne Dupraz-Poiseau,
Chief Devel. Officer -
John Cerio,
Chief Human Resource Officer -
Benjamin Navon,
Director of Corp. Communications -
Renee T. Leck,
Director of Investor Relations -
Dr. Fulvio Mavilio Ph.D.,
Chief Scientific Officer -
Dr. Nicoletta Loggia Ph.D.,
Chief Technical Officer -
Alicia Secor,
-
Steven Altschuler,
-
Marc Dunoyer,
-
James A Geraghty,
-
Llc Fmr,
-
Charles A Jr Rowland,
-
Capital Management, L.P.Ra ...,
-
Joanne T. Beck,
-
John T Curnutte,
-
Bobby Gaspar,
Chief Executive Officer -
Frank E Thomas,
See Remarks